New progress of blood purification therapy for sepsis

doi:10.3877/cma.j.issn.2095-3216.2020.05.005

Abstract

Abstract:

Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the host′s response to infection, and is an important cause of death in critically ill patients. In addition to the use of antibiotics, improvement of organ dysfunction, and necessary surgical treatment, various treatments of extracorporeal blood purification can also be used as an auxiliary treatment method for regulating inflammation in the current treatment of sepsis. Sepsis can induce an imbalance in the regulation of the immune system, which in turn leads to organ dysfunction. Blood purification, as an adjunct treatment of sepsis, aims to control the immune system-related imbalance of regulation via removing cytokines and endotoxins. This article reviewed the new progress of blood purification treatment for sepsis.

Key words: Sepsis, Blood purification

Jingkui Wu, Zhaohui Ni. New progress of blood purification therapy for sepsis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(05): 216-219.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.05.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I05/216

References 36

[9]	Ronco C. Endotoxin removal: history of a mission [J]. Blood Purif, 2014, 37(Suppl 1): 5-8.
[10]	Rimmele T, Kaynar AM, McLaughlin JN, et al. Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study [J]. Crit Care, 2013, 17(2): R59.
[11]	Kellum JA, Johnson JP, Kramer D, et al. Diffusive vs convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome [J]. Crit Care Med, 1998, 26(12): 1995-2000.
[12]	Rimmele T, Wey PF, Bernard N, et al. Hemofiltration with the Cascade system in an experimental porcine model of septic shock [J]. Ther Apher Dial, 2009, 13(1): 63-70.
[13]	Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure [J]. Crit Care Med, 2006, 34(8): 2099-2104.
[14]	Gruda MC, Ruggeberg KG, O′Sullivan P, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads [J]. PLoS One, 2018, 13(1): e0191676.
[15]	Sakai Y. Polymethylmethacrylate membrane with a series of serendipity [J]. Contrib Nephrol, 2011, 173: 137-147.
[16]	Payen D. Haemoperfusion with polymyxin B membrane: recent results for an old debate! [J]. Anaesth Crit Care Pain Med, 2019, 38(1): 3-4.
[17]	Adamik B, Zielinski S, Smiechowicz J, et al. Endotoxin elimination in patients with septic shock: an observation study [J]. Arch Immunol Ther Exp (Warsz), 2015, 63(6): 475-483.
[18]	Rogiers P, Zhang H, Pauwels D, et al. Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofiltration in canine endotoxic shock [J]. Crit Care Med, 2003, 31(4): 1219-1225.
[19]	Renaux JL, Thomas M, Crost T, et al. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH [J]. Kidney Int, 1999, 55(3): 1097-1103.
[20]	Chanard J, Lavaud S, Maheut H, et al. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane [J]. Nephrol Dial Transplant, 2008, 23(6): 2003-2009.
[21]	Yumoto M, Nishida O, Moriyama K, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration [J]. Ther Apher Dial, 2011, 15(4): 385-393.
[22]	Kobashi S, Maruhashi T, Nakamura T, et al. The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study [J]. Acute Med Surg, 2019, 6(1): 60-67.
[23]	Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices [J]. Intensive Care Med Exp, 2018, 6(1): 12.
[24]	Laville M, Dorval M, Fort Ros J, et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis [J]. Kidney Int, 2014, 86(6): 1260-1267.
[25]	Kessler M, Gangemi C, Gutierrez Martones A, et al. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study [J]. Hemodial Int, 2013, 17(2): 282-293.
[26]	Shum HP, Chan KC, Kwan MC, et al. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection [J]. Hong Kong Med J, 2013, 19(6): 491-497.
[27]	Tian Q, Gomersall CD, Ip M, et al. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration [J]. Antimicrob Agents Chemother, 2008, 52(3): 1009-1013.
[28]	De Vriese AS, Colardyn FA, Philippe JJ, et al. Cytokine removal during continuous hemofiltration in septic patients [J]. J Am Soc Nephrol, 1999, 10(4): 846-853.
[29]	McCrea K, Ward R, LaRosa SP. Removal of carbapenem-resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media [J]. PLoS One, 2014, 9(12): e114242.
[30]	Kang JH, Super M, Yung CW, et al. An extracorporeal blood-cleansing device for sepsis therapy [J]. Nat Med, 2014, 20(10): 1211-1216.
[31]	Buttner S, Koch B, Dolnik O, et al. Extracorporeal virus elimination for the treatment of severe Ebola virus disease--first experience with lectin affinity plasmapheresis [J]. Blood Purif, 2014, 38(3-4): 286-291.
[32]	Pino CJ, Yevzlin AS, Tumlin J, et al. Cell-based strategies for the treatment of kidney dysfunction: a review [J]. Blood Purif, 2012, 34(2): 117-123.
[33]	Pino CJ, Yevzlin AS, Lee K, et al. Cell-based approaches for the treatment of systemic inflammation [J]. Nephrol Dial Transplant, 2013, 28(2): 296-302.
[34]	Ding F, Song JH, Jung JY, et al. A biomimetic membrane device that modulates the excessive inflammatory response to sepsis [J]. PLoS One, 2011, 6(4): e18584.
[35]	Srisawat N, Tungsanga S, Lumlertgul N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients [J]. Crit Care, 2018, 22(1): 279.
[36]	Gossez M, Rimmele T, Andrieu T, et al. Proof of concept study of mass cytometry in septic shock patients reveals novel immune alterations [J]. Sci Rep, 2018, 8(1): 17296.
[1]	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
[2]	Shankar-Hari M, Deutschman CS, Singer M. Do we need a new definition of sepsis? [J]. Intensive Care Med, 2015, 41(5): 909-911.
[3]	Ankawi G, Neri M, Zhang J, et al. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls [J]. Crit Care, 2018, 22(1): 262.
[4]	Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies [J]. Curr Opin Crit Care, 2014, 20(6): 588-595.
[5]	Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis [J]. Artif Organs, 2003, 27(9): 792-801.
[6]	Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome [J]. J Pathol, 2004, 202(2): 145-156.
[7]	Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study [J]. J Infect Dis, 2004, 190(3): 527-534.
[8]	Peng ZY, Wang HZ, Carter MJ, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis [J]. Kidney Int, 2012, 81(4): 363-369.

Please choose a citation manager

Content to export